Sovaldi Sells Big in First Year

Share on Facebook
According to a Wall Street Journal report, Sovaldi, a newly approved drug to treat Hepatitis C, could see between $5 billion and $9 billion in sales during its first year on the market, one of the largest sales for a new drug's first year.

Read the full report on Becker's Hospital Review.

© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New from Becker's ASC Review

Transforming the OR Process: Instrumentation Makes a Difference

Read Now